KPI's P&L
LTM | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ||
Net sales (SEKm) | 204,7 | 180,9 | 155,5 | 96,6 | 129,3 | 104,6 | 61,8 | 41,0 | |
Sales growth (%) | 17,7 | 16,3 | 60,9 | -25,3 | 23,6 | 69,4 | 50,8 | 28,8 | |
Gross margin (%) | 89,2 | 89,4 | 87,4 | 84,3 | 87 | 84,4 | 84,6 | 84,4 | |
Operating loss (SEKm) | -85,6 | -98,6 | -158,1 | -174,4 | -99,3 | -88,7 | -53,9 | -39,3 |
1/ LTM refers to Latest Twelve Months (October 2020 - September 2021)
KPI's
Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | 2020 | 2019 | 2018 | 2017 | ||
Net sales (SEKm) | 54,9 | 51,8 | 44,8 | 53,2 | 48,1 | 180,9 | 155,5 | 96,6 | 129,3 | |
Sales growth (%) | 14,1 | 43,1 | 3,2 | 15,1 | 22,9 | 16,3 | 60,9 | -25,3 | 23,6 | |
Gross margin (%) | 89,0 | 89,5 | 88,6 | 89,8 | 91,4 | 89,4 | 87,4 | 84,3 | 87 | |
Operating loss (SEKm) | -13,3 | -25,9 | -19,7 | -26,7 | -19,2 | -98,6 | -158,1 | -174,4 | -99,3 | |
Loss for the period (SEKm) | -14,1 | -27,0 | -20,2 | -27,2 | -21,2 | -101,4 | -161,1 | -176,4 | -128,9 | |
Equity at period end (SEKm) | 284,9 | 359,7 | 380,1 | 398,9 | 425,1 | 398,9 | 124,3 | 278,5 | 450,8 | |
Net debt at period end (SEKm) | -214,5 | -300,3 | -328,9 | -343,3 | -367,3 | -343,3 | -81,7 | -261,5 | -434,7 | |
Cash at period end (SEKm) | 225,5 | 309,6 | 339,0 | 353,7 | 377,9 | 353,7 | 92,1 | 261,5 | 533,4 | |
Earnings per share before and after dilution (SEK) | -0,22 | -0,42 | -0,32 | -0,43 | -0,33 | -1,72 | -3,10 | -3,46 | -3,24 |
Income statement (SEKt)
Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | 2020 | 2019 | 2018 | 2017 | ||
Net sales | 54 877 | 51 777 | 44 829 | 53 175 | 48 078 | 180 860 | 155 462 | 96 623 | 129 301 | |
Cost of sales | -6 051 | -5 448 | -5 101 | -5 418 | -4 125 | -19 256 | -19 587 | -15 157 | -16 871 | |
Gross profit | 48 826 | 46 329 | 39 728 | 47 757 | 43 953 | 161 604 | 135 875 | 81 466 | 112 430 | |
Gross margin | 89,0% | 89,5% | 88,6% | 89,8% | 91,4% | 89,4% | 87,4% | 84,3% | 87,0% | |
Selling expenses | -35 507 | -34 090 | -31 153 | -33 884 | -31 982 | -123 818 | -160 139 | -132 211 | -92 858 | |
Sales commissions | -10 017 | -9 256 | -7 869 | -8 371 | -9 230 | -31 598 | -22 184 | -1 100 | 0 | |
Research & development expenses | -11 326 | -15 031 | -12 257 | -16 467 | -11 654 | -57 898 | -68 878 | -66 064 | -60 636 | |
Administrative expenses | -5 401 | -13 991 | -9 903 | -12 647 | -11 641 | -45 492 | -43 280 | -58 345 | -57 478 | |
Other operating income | 1 447 | 1 187 | 3 499 | 1 594 | 4 173 | 12 188 | 10 667 | 8 530 | 5 282 | |
Other operating expenses | -1 302 | -1 088 | -1 721 | -4 638 | -2 845 | -13 547 | -10 163 | -6 680 | -6 025 | |
Operating loss | -13 280 | -25 940 | -19 676 | -26 656 | -19 226 | -98 561 | -158 102 | -174 404 | -99 285 | |
Net financial items | -519 | -32 | -338 | 615 | -832 | -440 | -177 | -465 | -28 577 | |
Loss before income tax | -13 799 | -25 972 | -20 014 | -26 041 | -20 058 | -99 001 | -158 279 | -174 869 | -127 862 | |
Income tax | -269 | -1 073 | -201 | -1 124 | -1 171 | -2 411 | -2 781 | -1 536 | -1 007 | |
Loss for the period | -14 068 | -27 045 | -20 215 | -27 165 | -21 229 | -101 412 | -161 060 | -176 405 | -128 869 |
Balance sheet (SEKt)
ASSETS | Sep 30, 21 | Jun 30, 21 | Mar 31, 21 | Dec 31, 20 | Dec 31, 19 | Dec 31, 18 | Dec 31, 17 | |
Intangible assets | 8 358 | 8 523 | 8 742 | 8 840 | 7 679 | 5 511 | 5 244 | |
Tangible assets and right-of-use assets | 15 242 | 13 627 | 14 147 | 15 003 | 14 585 | 3 885 | 3 099 | |
Other non-current assets | 0 | 0 | 0 | 0 | 951 | 375 | 248 | |
Total non-current assets | 23 600 | 22 150 | 22 889 | 23 843 | 23 215 | 9 771 | 8 591 | |
Inventories | 47 725 | 45 367 | 46 681 | 45 555 | 39 331 | 23 681 | 22 079 | |
Trade receivables | 35 717 | 32 089 | 28 598 | 32 108 | 29 848 | 18 683 | 20 678 | |
Other operating receivables | 10 139 | 9 826 | 6 884 | 9 975 | 11 873 | 12 538 | 11 969 | |
Cash and cash equivalents | 225 497 | 309 559 | 338 956 | 353 737 | 92 065 | 261 468 | 533 367 | |
Total current assets | 319 078 | 396 841 | 421 119 | 441 375 | 173 117 | 316 370 | 588 093 | |
TOTAL ASSETS | 342 678 | 418 991 | 444 008 | 465 218 | 196 332 | 326 141 | 596 684 | |
EQUITY AND LIABILITIES | Sep 30, 21 | Jun 30, 21 | Mar 31, 21 | Dec 31, 20 | Dec 31, 19 | Dec 31, 18 | Dec 31, 17 | |
Equity | 284 921 | 359 667 | 380 066 | 398 899 | 124 309 | 278 531 | 450 786 | |
Leasing debt | 5 388 | 3 920 | 5 704 | 5 622 | 5 703 | 0 | 0 | |
Provisions | 329 | 329 | 329 | 329 | 305 | 289 | 173 | |
Total non-current liabilities | 5 717 | 4 249 | 6 033 | 5 951 | 6 008 | 289 | 173 | |
Leasing debt/current borrowings | 5 647 | 5 297 | 4 305 | 4 858 | 4 682 | 0 | 98 620 | |
Trade payables | 14 371 | 11 574 | 10 253 | 12 680 | 13 649 | 12 472 | 11 553 | |
Other operating liabilities | 32 022 | 38 204 | 43 351 | 42 830 | 47 684 | 34 849 | 35 352 | |
Total current liabilities | 52 040 | 55 075 | 57 909 | 60 368 | 66 015 | 47 321 | 145 725 | |
TOTAL EQUITY AND LIABILITIES | 342 678 | 418 991 | 444 008 | 465 218 | 196 332 | 326 141 | 596 684 |
Cash flows (SEKt)
Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | 2020 | 2019 | 2018 | 2017 | ||
Operating loss | -13 280 | -25 940 | -19 676 | -26 656 | -19 226 | -98 561 | -158 102 | -174 404 | -99 285 | |
Non-cash adjustments | 1 070 | 4 233 | -742 | 8 948 | 5 090 | 21 724 | 17 556 | 3 194 | 16 707 | |
Interest received | 0 | 0 | 0 | 1 | 0 | 5 | 98 | 82 | 3 | |
Interest paid | -57 | -60 | -3 | -3 | -735 | -6 | -36 | -868 | -11 740 | |
Other financial expenses paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 558 | 0 | |
Income tax paid | 133 | -363 | -309 | -1499 | -1081 | -4 970 | -5 210 | -2 151 | -737 | |
Net cash flows from operating activities before | -12 134 | -22 130 | -20 730 | -19 209 | -15 952 | -81 808 | -145 694 | -173 589 | -95 052 | |
changes in working capital | ||||||||||
Changes in working capital | -8 057 | -10 375 | 6 751 | -2 337 | -3 066 | -18 467 | -18 134 | 1 964 | -12 482 | |
Net cash flows from operating activities | -20 191 | -32 505 | -13 979 | -21 546 | -19 018 | -100 275 | -163 828 | -171 625 | -107 534 | |
Net cash flows from investing activities | -398 | -841 | -249 | -329 | -540 | -2 658 | -4 425 | -2 719 | -4 688 | |
Net cash flows from financing activities | -63 641 | 4 232 | -955 | -1 868 | 1 977 | 365 338 | -1 816 | -98 791 | 504 833 | |
Total cash flows for the period | -84 230 | -29 114 | -15 183 | -23 743 | -17 581 | 262 405 | -170 069 | -273 135 | 392 611 | |
Cash and cash equivalents as at beginning of period | 309 559 | 338 956 | 353 737 | 377 877 | 395 471 | 92 065 | 261 468 | 533 367 | 141 501 | |
Net exchange difference | 168 | -243 | 402 | -397 | -13 | -733 | 666 | 1 236 | -745 | |
Cash and cash equivalents as at period end | 225 497 | 309 599 | 338 956 | 353 737 | 377 877 | 353 737 | 92 065 | 261 468 | 533 367 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Bonesupport Holding AB published this content on 04 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2021 07:11:08 UTC.